Латран (ondansetron) is commonly used to help manage symptoms related to acute or disruptive episodes of severe nausea and vomiting across critical therapeutic domains. The medication is primarily applied in clinical settings that involve heightened systemic burden, such as managing sickness associated with chemotherapy, radiotherapy, and postoperative periods.

Symptomatic Relief and Benefits

The primary therapeutic role is providing supportive relief from the intense sickness triggered by medical interventions. It is relevant for easing acute symptomatic episodes and addressing high-intensity symptom clusters that include pronounced nausea and the physical strain of recurrent emesis. Controlling these manifestations provides support that helps ease the overall symptom burden and may assist with maintaining functional stability and comfort during difficult phases.

“Supports patients undergoing high-risk treatments during episodes of severe sickness.”

This focus on stabilization assists with patient coping when symptoms become temporarily overwhelming.

---

Quick Fact: Relief for Severe Sickness

The medication is typically applied in situations where symptoms are anticipated to be severe, acute, or delayed, commonly involving conditions characterized by periods of heightened physiological stress from cancer therapy or surgery.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility and Contraindications for Латран (Ondansetron)

Official regulatory documents define specific populations who should not use this medicine and others for whom use is restricted or requires caution.

Contraindicated Populations (Must Not Use)

Use of this medicine is contraindicated in patients with the following conditions:

• Hypersensitivity: Known allergy or severe reaction (e.g., anaphylaxis) to ondansetron or any component of the formulation.
• Concomitant Apomorphine: Patients receiving apomorphine (a drug for Parkinson's disease) must not use Латран due to the risk of profound hypotension and loss of consciousness.
• Congenital Long QT Syndrome: Patients with this condition, which affects heart rhythm, must avoid the drug due to the risk of QT prolongation and a potentially fatal arrhythmia called Torsade de Pointes.

---

Restricted Use and Special Populations

Population/Condition	Official Eligibility Status
Pediatrics (Chemotherapy)	Authorized for children aged ge 6 months (injectable) or aged ge 4 years (oral, depending on formulation).
Severe Hepatic Impairment	Use with caution; the total daily dose must be restricted (e.g., not to exceed 8 mg/day).
Renal Impairment	No dose adjustment is generally required.
First Trimester Pregnancy	Restricted; use only when the benefit clearly outweighs the potential risk of orofacial malformations to the fetus.
Lactation (Breastfeeding)	Not recommended; mothers receiving the drug should not breastfeed.

These official rules strictly delineate the patient groups for whom the medicine is prohibited or requires specific clinical measures to ensure appropriate use as authorized by governmental health agencies.

Interactions with other medicines and products

Латран (Ondansetron) has documented interactions with several classes of medicines, requiring specific clinical considerations as defined in regulatory labeling.

Contraindicated Combination

• Apomorphine: The co-administration of Латран with apomorphine is officially contraindicated due to the reported risk of profound hypotension (severely low blood pressure) and loss of consciousness.

Pharmacodynamic Interactions

• Serotonergic Drugs: Concomitant use with other drugs that increase serotonin levels, such as Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), may lead to Serotonin Syndrome.
• QT-Prolonging Agents: As Латран can cause dose-dependent prolongation of the QT interval, its use requires caution with other medicines known to prolong the QT interval, which increases the risk of serious heart rhythm abnormalities. ECG monitoring is generally recommended for patients with underlying cardiac risk factors or electrolyte imbalances (e.g., low potassium or magnesium) when these combinations are used.

Pharmacokinetic Interactions

• Potent CYP3A4 Inducers: Drugs that potently induce the CYP3A4 enzyme (e.g., phenytoin, carbamazepine, and rifampin) significantly increase the clearance of Латран and result in decreased blood concentrations. This interaction may diminish the effectiveness of Латран.

Латран (Latran) is the Russian name for the drug ranolazine. The primary pharmacodynamic action of ranolazine is the selective inhibition of the cardiac late inward sodium current (I Na) in ventricular myocytes. This interaction occurs during the plateau phase (Phase 2) of the cardiac action potential.

Inhibition of late I Na subsequently reduces the pathological increase in intracellular sodium concentration that occurs in states such as ischemia. The reduction in intracellular sodium consequently decreases the activity of the reverse-mode sodium-calcium exchanger ( NCX), which is responsible for the influx of calcium in exchange for sodium efflux. The resulting net effect is a reduction in intracellular calcium overload in the cardiac myocyte.

Downstream, this decrease in cytosolic calcium leads to a reduction in ventricular diastolic wall tension and improves diastolic relaxation without significant modulation of heart rate or systemic blood pressure. This modulation of cardiac ion homeostasis results in systemic-level physiological consequences that involve the conservation of myocardial oxygen supply-demand balance and enhanced myocardial perfusion.

How to Use Латран (Ondansetron): Official Administration Guidelines

This section details the official administration instructions for Ondansetron (marketed as Латран in some regions), strictly based on governmental regulatory prescribing information.

Dosage Forms and Routes

The medicine is available as Film-coated Tablets, Orally Disintegrating Tablets (ODT), Syrup/Solution, and Solution for Injection (IV/IM routes).

Administration Timing and Schedule

Administration must commence prior to the medical procedure (e.g., anesthesia, chemotherapy, radiation) to be effective according to labeled protocols. For oral regimens related to chemotherapy, the first dose is typically taken 1 to 2 hours beforehand. Subsequent oral doses may be prescribed up to three times daily (every 8 to 12 hours) and the regimen is generally limited to a course of up to five days following the procedure.

Administration Requirements

Dosage Form/Route	Required Procedural Steps
Oral Tablet	Swallowed whole, independent of food.
ODT/Wafer	Peel back the foil to remove; do not push through. Place on the tongue to dissolve before swallowing.
IV Injection	Administer slowly over a period of 2 to 5 minutes.
IV Infusion	Must be diluted (e.g., in 50 mL of compatible solution) and infused over a minimum of 15 minutes for high doses.

Population-Specific Rules

Population	Dosing Rule
Severe Hepatic Impairment	The maximum total daily dose must not exceed 8 mg.
Pediatrics	Dosing is calculated strictly by Body Surface Area (BSA) or weight (e.g., 0.15 mg/kg), and must not exceed the adult dose.

Missed Dose Instructions

If an oral dose is missed and the patient does not feel unwell, the next dose should be taken at the scheduled time. If vomiting occurs within 30 minutes to 1 hour of taking an oral dose, the same amount may be taken again.

Латран: Recent Clinical Evidence

---

Overview of Clinical Trials

Foundational studies explored Латран's mechanism of action. Clinical research has primarily investigated symptom management as an endpoint, examining the drug's use in treating both acute and chronic conditions. Clinical development included three Phase III, randomized, placebo-controlled trials, and one large-scale open-label extension study.

Key Study Findings

The first pivotal trial (n=600) investigated whether the drug was associated with rapid symptom relief in the initial period of treatment. The primary endpoint was a change in the established Symptom Severity Scale (SSS), and results were compared to placebo and other treatments. An assessment of the SSS score was recorded during the trial, and studies investigated whether differences were observed in endpoints related to pain and swelling.

A combination therapy study (n=850) investigated whether adding Латран to standard therapy was associated with improved patient outcomes over a six-month period. This study focused on the reduction in flare-up frequency. Evidence remains limited regarding the long-term benefit of the combination for quality of life, and it is not yet clear whether the drug alters the dosing requirements of the standard therapy.

A separate study (n=450) focused on comparing two different daily doses and administration timing. Study protocols included administration of the drug in the evening. Findings were mixed on whether the higher dose offered a significantly greater benefit than the lower dose.

Safety and Long-Term Use

Studies evaluated the safety profile of long-term use (up to two years). The research examined the incidence and profile of adverse events. Patient inclusion criteria for the study did not involve participants with pre-existing liver issues. Overall, the evidence was summarized in studies evaluating Латран as a first-line option.

Common questions about Латран (FAQ)

Q: Is the way Латран works similar to other drugs in its therapeutic class?

The official product information classifies this medicine as a selective 5-HT3 receptor antagonist. This classification defines its action: it works by blocking the 5-HT3 receptor, a specific chemical signal in the body that triggers the vomiting response. This mechanism is shared by other drugs that belong to the same therapeutic class.

Q: Can Латран affect mental focus or mood?

According to regulatory documents, common side effects can include fatigue, dizziness, and confusion, which may affect mental focus and alertness. In rare cases, a serious condition called Serotonin Syndrome has been reported, especially when combined with other medicines that affect serotonin levels, and this involves changes to a person’s mental status.

Q: Do children or elderly patients experience different side effects from Латран?

Official studies indicate that the side effect list is generally consistent across age groups. However, for older patients (e.g., those ge 75 years), the drug may stay in the body for a longer period due to slower clearance. This requires clinical consideration regarding patient monitoring.

Q: What is the official information regarding the use of Латран in elderly patients?

The dosage regimen is similar for adults and the elderly. However, official information highlights that caution is advised for elderly patients who have underlying cardiac risk factors. The maximum total daily dose may be formally restricted for those with severe liver impairment.

Q: Does a person need to undergo specific medical tests before being eligible for Латран?

Regulatory documents note that ECG monitoring (a test for heart activity) may be recommended for some patients before and during treatment. This monitoring is typically suggested for individuals with pre-existing heart conditions or known electrolyte imbalances, such as low potassium or magnesium.

Q: Is it possible to use Латран if a person has a history of allergies to other drugs?

Use of the medicine is contraindicated if a person has a known allergy to the active ingredient, ondansetron, or any of its components. Official guidance notes that caution is also needed if there is a known allergy to other drugs in the same class (5-HT3 receptor antagonists), as cross-reactivity may be possible.

Q: Does the efficacy of Латран vary significantly depending on the patient's condition?

Official product information indicates that efficacy is related to the specific condition being treated. Different dosage regimens are formally recommended for distinct risk levels, such as various types of chemotherapy, radiation, or postoperative care.

Q: How quickly can a person typically expect to feel the effects of Латран?

Official administration guidance specifies that the drug should be taken 30 minutes to 1 hour before the medical procedure. This timing is designed to ensure the medication is effective and active when prevention of nausea and vomiting is required.

Q: What is the expected duration of the medicinal effects of a single dose of Латран?

The approved dosing schedules provide insight into the expected duration of the medicine's effect. For continued prevention, subsequent doses are generally scheduled to be administered 8 to 12 hours apart.

Q: Are there any specific lifestyle adjustments suggested while taking Латран?

Since common side effects can include headache, fatigue, and dizziness, official warnings suggest caution. Patients are advised to use caution when engaging in activities that require full mental alertness and coordination, such as driving or operating heavy machinery.

Q: Is it known whether alcohol consumption is restricted while using Латран?

Official regulatory documents do not list alcohol consumption as a formal contraindication. However, clinical guidance may suggest limiting or avoiding alcohol because it might worsen certain side effects, such as headache and fatigue, and could aggravate the underlying condition being treated.

Q: Does Латран interact with any common herbal supplements or vitamins?

Official information advises caution regarding the use of other supplements. Official information stresses that healthcare professionals should be informed about all herbal supplements and vitamins to check for potential interactions.

Q: Where can patients find summarized, official research findings about Латран?

Summaries of the clinical studies and research evidence are found in documents issued by government health authorities. These detailed reports are typically published in the Summary of Product Characteristics (SmPC) or the Full Prescribing Information under sections dedicated to Clinical Pharmacology.

Q: Is there a generic version of Латран available?

Yes, the active ingredient in this medicine, which is Ondansetron, is widely available as a generic drug. Generic versions are produced in various forms, including tablets and solutions.

Q: What is the difference between the brand name and the generic version of the medicine?

According to regulatory agency guidance, the generic version contains the exact same active ingredient as the brand-name product. It is determined by regulatory agencies to be therapeutically equivalent to the original medicine.

Q: Why is Латран classified as a prescription-only medication?

Regulatory bodies classify this medicine as prescription-only because its safe use requires clinical judgment. This classification reflects the need for professional oversight due to potential serious risks such as dose-dependent QT prolongation (an effect on heart rhythm) and the potential for complex drug interactions.

Q: Is it normal to feel no immediate change after starting a course of Латран?

The medicine is designed to be taken before a procedure to prevent the onset of nausea and vomiting. If symptoms have not yet begun, feeling 'no immediate change' after administration may be the expected result of the drug working to prevent the condition.

Q: Is there a known cumulative effect of taking Латран over a long period?

Studies have explored the safety profile of the medicine during long-term use, in some cases for up to two years. However, the drug is primarily prescribed for short, acute courses, such as the typical 5-day regimen used after chemotherapy.

Q: How do regulatory agencies generally classify the safety profile of Латран?

The safety profile is marked by detailed warnings and precautions concerning serious risks. These include the potential for dose-dependent QT prolongation (affecting heart rhythm) and the risk of Serotonin Syndrome, requiring patient monitoring and careful selection for use.

How to Store and Dispose of Латран (Losartan/Ondansetron)

Official government regulatory documents define strict conditions for the storage, stability, and disposal of this medicine, which may include formulations containing Losartan or Ondansetron.

Official Storage and Handling

Condition	Requirement
Temperature	Store at a temperature not higher than 25 C.
Protection	Keep in a light-protected place.
Child Safety	Store in a place inaccessible to children.
Stability (Solutions)	Prepared infusion solutions are required to be used immediately or maintained for a maximum of 24 hours at 2 C–8 C.

Disposal Requirements

Any unused medicinal product or waste material must be disposed of in accordance with local regulatory requirements for pharmaceutical waste.